Fc 受体 (FcR) 是一类能够识别并结合免疫球蛋白 Fc 段的细胞表面受体,在免疫应答和免疫调节等过程中发挥重要作用。按照识别的免疫球蛋白类型 Fc 受体可分为 FcγR、FcεR 和 FcαR 等。按照功能特性可分为激活型 Fc 受体和抑制型 Fc 受体。Fc 受体可介导免疫细胞的吞噬作用,促使吞噬细胞清除病原体等抗原性异物。Fc 受体也参与 ADCC,激活 NK 细胞等杀伤靶细胞,影响免疫应答。此外,Fc 受体可以清除免疫复合物,防止其在组织中沉积引发炎症。Fc 受体功能异常或表达的失调可引发自身免疫性疾病和过敏性疾病,在肿瘤中既涉及肿瘤细胞的免疫逃逸又可作为免疫治疗的作用靶点[1][2]。
Fc Receptors (FcR) are a class of cell surface receptors that can recognize and bind to the Fc region of immunoglobulins, playing an important role in processes such as the immune response and immune regulation. According to the types of immunoglobulins they recognize, FcR can be classified into FcγR, FcεR, FcαR, etc. According to their functional characteristics, they can be divided into activating FcR and inhibitory FcR. FcR mediate the phagocytosis of immune cells, prompting phagocytes to eliminate antigenic foreign substances such as pathogens. FcR also participate in ADCC, which activates NK cells and other cells to kill target cells, affecting the immune response. In addition, FcR can clear immune complexes and prevent them from depositing in tissues and triggering inflammation. Abnormal functions or dysregulated expressions of FcR can lead to autoimmune diseases and allergic diseases. In tumors, FcR are involved in both the immune escape of tumor cells and can serve as targets for immunotherapy[1][2].
Anti-CD32b/FCGR2B Antibody (2B6) 是一种靶向 CD32B 的人源单克隆抗体,可用于 B 细胞淋巴瘤的研究。
BI-1206 是一种靶向 FcγRIIB (CD32B) 的重组拮抗性人源单克隆抗体,可阻断 Rituximab (MS-Q15663) 本身或与 Ibrutinib (MS-M40234)、Venetoclax (MS-S50888) 和 CHOP 联合使用时诱导的 CD20 内化,增强或恢复 Rituximab 或其他抗 CD20 单克隆抗体的活性,具有对抗恶性 B 细胞的细胞溶解活性,可用于研究套细胞淋巴瘤 (MCL) 等癌症。
BI-1607 是一种靶向 CD32b/FcγRIIB 的人源化单克隆抗体,具有拮抗作用,能够阻断 FcγRIIB 对免疫效应细胞的抑制作用,与 Trastuzumab (MS-U55108) 联合使用时,可显著抑制 HER2 阳性实体瘤,包括晚期胃癌 (GC)。
C201-0243 是一种 FcRn 拮抗剂,对 IgG-FcRn 结合具有拮抗活性(IC50 为 3.439 nM),可用于 IgG 介导的自身免疫性疾病的研究。
© 2026 MolStrong. 保留所有权利。粤ICP备2023004355号
可通过CAS号进行批量搜索,一行一个CAS号